Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Wordpress Themes And Plugins
  7. Keywords
  8. Topics
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021366, but it redirected us to https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021366. The analysis below is for the second page.

Title[redir]:
No title found...
Description:
The cancer-testis (CT) family of antigens is expressed in a variety of malignant neoplasms. In most cases, no CT antigen is found in normal tissues, except in testis, making them ideal targets for cancer immunotherapy. A comprehensive analysis of CT antigen expression has not yet been reported in prostate cancer. MAGE-C2/CT-10 is a novel CT antigen. The objective of this study was to analyze extent and prognostic significance of MAGE-C2/CT10 protein expression in prostate cancer. 348 prostate carcinomas from consecutive radical prostatectomies, 29 castration-refractory prostate cancer, 46 metastases, and 45 benign hyperplasias were immunohistochemically analyzed for MAGE-C2/CT10 expression using tissue microarrays. Nuclear MAGE-C2/CT10 expression was identified in only 3.3% primary prostate carcinomas. MAGE-C2/CT10 protein expression was significantly more frequent in metastatic (16.3% positivity) and castration-resistant prostate cancer (17% positivity; p<0.001). Nuclear MAGE-C2/CT10 expression was identified as predictor of biochemical recurrence after radical prostatectomy (p = 0.015), which was independent of preoperative PSA, Gleason score, tumor stage, and surgical margin status in multivariate analysis (p<0.05). MAGE-C2/CT10 expression in prostate cancer correlates with the degree of malignancy and indicates a higher risk for biochemical recurrence after radical prostatectomy. Further, the results suggest MAGE-C2/CT10 as a potential target for adjuvant and palliative immunotherapy in patients with prostate cancer.

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Science

Content Management System {📝}

What CMS is doi.org built with?


Doi.org operates using WORDPRESS. But there are also traces of other content systems on the page (hubspot).

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌍 Impressive Traffic: 500k - 1M visitors per month


Based on our best estimate, this website will receive around 600,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We're unsure if the website is profiting.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Doi.org might be making money, but it's not detectable how they're doing it.

Wordpress Themes and Plugins {🎨}

What WordPress theme does this site use?

It is strange but we were not able to detect any theme on the page.

What WordPress plugins does this website use?

It is strange but we were not able to detect any plugins on the page.

Keywords {🔍}

cancer, expression, magecct, prostate, article, view, google, scholar, patients, antigens, nyeso, antigen, tumor, nuclear, prostatectomy, radical, tissue, plos, staining, image, cells, protein, cancertestis, gleason, gene, figure, advanced, independent, analysis, study, psa, stage, castration, res, recurrence, prognostic, identified, metastatic, disease, magea, positive, clinical, original, treatment, melanoma, tumors, cell, table, immunoreactivity, mage,

Topics {✒️}

ventana medical systems cookies plos open-access article distributed parametric mann-whitney u-test plos mage-c2/ct10 positive tumors mage-c2/ct10 negative tumors mage-c2/ct10 protein expression mage-c2/ct10 mrna expression nuclear mage-c2/ct10 expression results suggest mage-c2/ct10 nuclear mage-c2/ct10 immunoreactivity including mage-c2/ct10 expression positive mage-c2/ct10 expression rare mage-c2/ct-10 expression contributed reagents/materials/analysis tools ny-eso-1 t-cell epitope asymptomatic low-stage tumors mage-c2/ct10 protein castration-recurrent prostate tumors mage-c2/ct10 belongs t001 mage-c2/ct10 study identified mage-c2/ct-10 cancer/testis antigen ny-eso-1 mage-c2/ct10 expression recombinant ny-eso-1 protein antigen ct10/mage-c2 sided log-rank statistics mage-c2/ct10 immunoreactivity high-throughput molecular profiling organ-confined prostate cancer ny-eso-1 protein expression mage-c2/ct-10 expression tumor-specific antigen encoded ny-eso-1 mrna expression mage-c2/ct-10 antibody paraffin-embedded prostate tissues mage-positive cell lines cancer-related serological recognition serum prostate-specific antigen low-grade prostate cancer androgen-refractory prostate cancer original author high-grade urothelial carcinomas found mage-c2/ct10 mage-c1/ct-7 gene suppress p53-dependent apoptosis cancer/testis antigen expression cancer-testis antigen expression identify representative areas

External Links {🔗}(232)

Analytics and Tracking {📊}

  • Facebook Pixel
  • Google Analytics
  • Google Analytics 4
  • Google Tag Manager
  • Google Universal Analytics
  • HubSpot

Libraries {📚}

  • Foundation
  • jQuery
  • Leaflet
  • Lightbox
  • Modernizr
  • Moment.js
  • Underscore.js
  • Video.js
  • Vue.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Cloudflare
  • Crossref

6.09s.